剑桥科技(06166)控股子公司通过高新技术企业认定 智谱(02513)回应与出行平台合作不涉内幕消息 业务推进属日常范畴 重大事项： 红星冷链(01641)：香港公开发售获2309.25倍认购 每股发售价12.26港元 BBSB INTL(08610)：公开发售获10745.13倍认购 每股发售价0.6港元 兆易创新(03986)香港公开发售获542.22倍认购 全球发售净筹约46.11亿港元 恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单 百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗 体双药物偶联物项目 东风集团股份(00489)2025年度累计汽车销量为189.62万辆 同比增长约0.01% 中银航空租赁(02588)2025年全年自有飞机利用率保持在100% 龙湖集团(00960)2025年度累计实现总合同销售金额631.6亿元 中国软件国际(00354)投资企业MiniMax(00100)港交所上市 全栈AI战略版图再拓新篇 达力普控股(01921)拟300万沙特里亚尔出售达力普国际40%股权 引入沙特战略投资者推 ...

Core Viewpoint - WuXi AppTec (603259.SH) has released an earnings forecast for 2025 that exceeds its previously raised guidance, indicating strong revenue and net profit growth driven by its integrated CRDMO model and non-recurring gains from asset disposals [1] Group 1: Financial Performance - The company expects to achieve a total revenue of 45.456 billion yuan in 2025, representing a year-on-year increase of 15.84%, with core business revenue growing approximately 21.40% [1] - Adjusted net profit attributable to shareholders is projected to be 14.957 billion yuan, reflecting a year-on-year growth of about 41.33%, while net profit attributable to the company’s shareholders is expected to reach 19.151 billion yuan, marking a significant increase of approximately 102.65% [1] - The company has raised its annual revenue guidance for the second time within a year, adjusting the expected range from 42.5-43.5 billion yuan to 43.5-44 billion yuan [1] Group 2: Business Segments - The TIDES business (oligonucleotides and peptide drugs) has shown remarkable performance, with revenue reaching 7.84 billion yuan in the first three quarters, a year-on-year increase of 121.1%, setting historical highs for both the first three quarters and the third quarter [2] - Non-recurring gains from asset disposals have significantly contributed to the earnings exceeding expectations, with net gains from the sale of certain equity stakes totaling 5.595 billion yuan, accounting for 37.41% of the expected annual net profit [2] Group 3: Strategic Focus - The company is focusing on its core CRDMO areas by divesting from clinical research services, which has resulted in a gain of 1.434 billion yuan from the sale of related businesses [2] - WuXi AppTec is expanding its global footprint with ongoing construction of overseas bases in Singapore and Delaware, aiming to mitigate geopolitical risks and better meet customer demands [3] - Revenue from U.S. clients has reached 22.15 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 31.9% and increasing its share of total revenue to 67%, becoming a key growth driver [3]

今日焦点 华是科技：控股股东、实际控制人等筹划控制权变更事项，股票停牌 华是科技公告称，公司控股股东、实际控制人俞永方、叶建标和持股5%以上股东章忠灿正在筹划重大 事项，可能导致公司控制权发生变动。为保证公平信息披露，维护投资者利益，避免造成公司股价异常 波动，公司股票自2026年1月13日开市起停牌，预计停牌时间不超过2个交易日。停牌期间，公司将根据 事项进展情况，严格按照法律法规的规定和要求履行信息披露义务。待上述事项确定后，公司将及时披 露相关公告并申请公司股票复牌。 卓易信息发布异动公告，公司IDE业务在2024及2025年陆续发布了两款AI编程产品，尚处于市场导入 期，在初步商业化阶段，产品技术路径、编程效果及市场接受度存在不确定性，目前尚未形成规模化的 产品体系，技术迭代及商业化进展可能不及预期。目前两款产品使用用户以免费用户为主，尚未形成稳 定、可持续的收入来源。未来产品的收入规模、盈利水平及现金流贡献存在高度不确定性，短期内对公 司整体经营业绩影响有限。DeepSeek、通义千问等均系开源大语言模型，任何用户皆可免费基于该模 型开展训练工作，进而进行个性化开发或模型优化，以满足不同用户在多元场 ...

Core Viewpoint - WuXi AppTec expects to achieve a revenue of approximately RMB 4,545,617 million in 2025, representing a year-on-year growth of about 15.84% [1] - The revenue from continuing operations is projected to grow by approximately 21.40% year-on-year [1] - The company anticipates a net profit attributable to shareholders of approximately RMB 1,915,058 million, reflecting a year-on-year increase of about 102.65% [1] Summary by Category - **Revenue Projections** - Expected revenue for 2025 is approximately RMB 4,545,617 million, with a growth rate of 15.84% compared to the previous year [1] - Revenue from continuing operations is projected to grow by 21.40% year-on-year [1] - **Net Profit Expectations** - Anticipated net profit for shareholders is around RMB 1,915,058 million, indicating a significant increase of 102.65% year-on-year [1]

Core Viewpoint - WuXi AppTec has raised its revenue forecast for 2025 for the third time, indicating strong growth potential in its business operations [1] Group 1: Revenue Forecast - The company expects to achieve approximately 45.456 billion yuan in revenue for 2025, representing a year-on-year growth of about 15.84% [1] - Revenue from continuing operations is projected to grow by approximately 21.40% year-on-year [1] - The previous revenue forecast was adjusted from a range of 42.5 billion to 43.5 billion yuan to a new range of 43.5 billion to 44 billion yuan [1] Group 2: Profitability - The company anticipates a net profit attributable to shareholders of approximately 19.151 billion yuan for 2025, reflecting a year-on-year increase of about 102.65% [1] - This net profit is expected to set a new historical high for the company [1]

Core Viewpoint - WuXi AppTec (603259.SH, 02359.HK) has raised its revenue forecast for 2025 for the third time, expecting approximately 45.456 billion yuan in revenue, a year-on-year increase of about 15.84%, with a significant net profit forecast of around 19.151 billion yuan, representing a 102.65% increase year-on-year, marking a historical high for the company [1][3]. Group 1 - The company expects 2025 revenue to reach approximately 45.456 billion yuan, with a year-on-year growth of about 15.84%, and a 21.40% increase in revenue from continuing operations [1]. - The previous revenue forecast was adjusted from 42.5-43.5 billion yuan to 43.5-44 billion yuan during the Q3 report [1]. - The anticipated net profit for 2025 is approximately 19.151 billion yuan, which is a historical high and represents a year-on-year increase of about 102.65% [1][3]. Group 2 - The company focuses on a unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing production efficiency and expanding capabilities to drive steady business growth [3]. - Significant net profit contributions are expected from the sale of assets, including approximately 4.161 billion yuan from the sale of shares in WuXi AppTec's subsidiary and about 1.434 billion yuan from the sale of 100% equity in two clinical research companies, totaling nearly 5.6 billion yuan in net gains [3]. - The asset sales align with the company's strategy to focus on the CRDMO business model, providing funding support for global capacity expansion [3].

★ 宏观动态 ★ 商务部发布关于中欧电动汽车案磋商进展的通报 据中国商务部网站，为落实中欧领导人会晤共识，妥善解决欧盟对华电动汽车案，中欧双方本着相互尊重的态 度，进行了多轮磋商。双方一致认为，有必要向对欧盟出口纯电动汽车的中国出口商，提供关于价格承诺的通 用指导，以便中国出口商可通过更加实用、有针对性且符合世贸组织规则的方式，解决相关关注。为此，欧方 将发布《关于提交价格承诺申请的指导文件》，并在文件中确认，欧方将秉持非歧视原则，根据世贸组织规则 有关规定，对每一项价格承诺申请，适用相同法律标准，并以客观和公正的方式进行评估。这充分体现了中欧 双方的对话精神和磋商成果。中欧双方有能力、有意愿，在世贸组织规则框架下，通过对话磋商妥善化解分 歧，维护中欧及全球汽车产业链供应链稳定。这不仅有利于中欧经贸关系健康发展，也有利于维护以规则为基 础的国际贸易秩序。 摩根大通：AI需求井喷将推动基建与机器人领域并购浪潮 摩根大通指出，人工智能需求的爆发式增长及海量资本涌入AI产业，正推动电力系统、热管理、机器人及工 业软件领域形成并购热点。据该行预测，全球对数据中心、AI基础设施及相关电力供应的投资规模预计将达5 万亿— ...

Core Viewpoint - WuXi AppTec (药明康德) anticipates an increase in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, driven by its integrated CRDMO business model and strategic asset sales [1][2]. Group 1: Financial Performance - The company expects to achieve revenue of approximately RMB 45,456.17 million, representing a year-on-year growth of about 15.84%, with a 21.40% increase in revenue from continuing operations [1]. - Adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56% [1]. - The total net profit attributable to shareholders is anticipated to be around RMB 19.151 billion, showing a significant year-on-year growth of approximately 102.65% [1]. - Basic earnings per share are expected to be approximately RMB 6.70, representing a year-on-year increase of about 104.27% [1]. Group 2: Business Strategy and Operations - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, enhancing capabilities and building new production capacity to meet customer demands [2]. - The impact of non-recurring gains on net profit primarily stems from the sale of a portion of its stake in WuXi XDC Cayman Inc., expected to yield a net gain of approximately RMB 4.161 billion, and the sale of 100% stakes in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., expected to yield a net gain of approximately RMB 1.434 billion [2].

Core Viewpoint - WuXi AppTec is expected to achieve significant revenue and profit growth in 2025, driven by its core business operations and strategic asset sales [1] Financial Performance - The company anticipates total revenue of approximately RMB 45.46 billion for 2025, representing a year-on-year increase of about 15.8% [1] - Revenue from continuing operations is projected to grow by approximately 21.4% year-on-year [1] - The expected net profit attributable to shareholders is around RMB 19.15 billion, reflecting a substantial year-on-year growth of approximately 102.6% [1] - The basic earnings per share for 2025 is estimated to be about RMB 6.70, which indicates a year-on-year increase of approximately 104.3% [1]

Core Viewpoint - A-shares experienced a significant surge, with record trading volumes and a notable influx of foreign capital, indicating a strong market sentiment and potential for further growth [1][6][14]. Market Performance - On January 12, 2026, the Shanghai Composite Index rose by 1.09% to 4165.29 points, the Shenzhen Component Index increased by 1.75% to 14366.91 points, and the ChiNext Index climbed by 1.82% to 3388.34 points [14]. - The total trading volume across the three markets reached a record high of 36,449.71 billion, with over 4,100 stocks rising and 202 stocks hitting the daily limit [15]. Foreign Capital Inflow - In the first week of January 2026, northbound capital saw a net inflow of 9.6 billion, reversing the previous week's outflow of 3.1 billion [6]. - Active foreign capital participation was noted, particularly in stocks like CATL, which accounted for 20% of the total trading volume in the week [6]. Sector Performance - The A-share market's upward momentum was primarily driven by the electronics, military, and non-ferrous metals sectors, which collectively contributed over half of the index's gains [8]. - The AI application sector, including AI healthcare and marketing, saw significant growth, with several stocks reaching their daily limit [15]. Generative Engine Optimization (GEO) Market - The GEO market in China is projected to grow significantly, with a year-on-year increase of over 200% expected by Q2 2025, and the market size anticipated to reach 2.9 billion by 2030 [10]. - Companies involved in GEO, such as BlueFocus and Zhejiang Wenlian, are positioning themselves to capitalize on this emerging trend [11][12]. Notable Company Developments - WuXi AppTec projected a net profit of 19.151 billion for 2025, marking a 103% increase year-on-year, driven by asset sales and business restructuring [24]. - Xpeng Motors is preparing for an IPO of its flying car division in Hong Kong, with major investment banks involved in the process [21]. Investment Opportunities - The surge in AI-related stocks presents potential investment opportunities, particularly in companies that are integrating AI technologies into their business models [15]. - The commercial aerospace sector is also gaining traction, with significant developments in satellite technology and related companies seeing increased stock performance [20].